Group items tagged

PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.

AstraZeneca has completed the acquisition of Bristol-Myers Squibb's (BMS's) interests in the companies' diabetes alliance for $4.1bn.

GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.